Skip to main content

Table 2 Results of 68Ga-PSMA PET/CT and 18FDG PET/CT

From: 68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617

No. Primary tumor Moment of scan Site (Median) SUVmax Range
PSMA FDG
1 2008 2017 No pathological uptake  
2018 Leptomeningeal/drop metastases Th10 2.66   2.66
2018 No pathological uptake  
2 2008 2017 Lungs   5.02 4.46–5.35
Th4   2.94 2.94
2017 Lungs   5.45 4.54–7.99
Th4   2.79 2.79
2017 Left cervical lymph nodes 3.33   3.04–3.61
Lungs 8.03   7.65–9.40
Liver 7.18   5.84–8.52
2017 Left cervical lymph nodes 3.82   2.90–4.73
Decrease in lungs 8.67   6.56–10.56
Decrease in liver 6.01   6.01
2018 Unchanged left cervical lymph nodes   4.20 4.00–2.40
Increase in lungs   5.44 5.07–8.16
3 2013 2016 Lungs   1.85 0.93–2.66
2017 Lungs 3.61   1.31–4.66
2018 Recurrence/metastasis central compartment   3.61 3.61
Lungs   3.21 2.27–4.89
4 2010 2016 Residual thyroid bed   4.55 4.55
Lungs   4.44 2.51–7.51
Mediastinal/hilar lymph nodes   15.31 11.03–26.24
Lymph node m. pectoralis   1.93 1.93
Lymph node parasternal   1.37 1.37
2016 Residual thyroid bed 1.38   1.38
Lungs 1.54   1.28–1.79
Mediastinal/hilar lymph nodes 2.42   2.26–6.97
Lymph node m. pectoralis 0.85   0.85
5 1996 2016 Right cervical lymph nodes 4.35   3.56–5.13
Lungs 1.73   1.44–3.39
2017 Right cervical lymph nodes   3.35 2.12–8.36
Retropharyngeal   5.43 5.43
Lungs   2.85 1.83–3.76
2017 Right cervical lymph nodes   3.99 3.57–4.50
Retropharyngeal   5.82 5.82
Lungs   3.44 2.49–5.49
  1. Entries in bold are newly diagnosed on 68Ga-PSMA PET/CT